Digital Therapeutics Market is expected the compound annual growth rate (CAGR 31.6%) : An Overview of Latest Developments and Trends | Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), Cog

Digital therapeutics (DTx) are software-based treatments that are designed to help improve patient outcomes and reduce healthcare costs. They are an emerging field of healthcare technology that uses digital therapeutics to deliver evidence-based interventions to improve patient health outcomes.

To know about the assumptions considered for the study download the pdf brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724&utm_source=Openpr&utm_campaign=paid&utm_content=referral

The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period. Increasing prevalence of chronic diseases, developments in digital therapeutics to curb growing healthcare costs and government initiatives to support the digital therapeutics are driving the market growth.

Key Market Players

The digital therapeutics market is a highly diversified and competitive market, with several emerging players. The prominent players in this market include are Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), CogniFit Inc (US), Ginger (US), Propeller Health (US), 2Morrow, Inc. (US), Canary Health (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Twill Inc. (US), Better Therapeutics, Inc (US), Mindstrong (US), Kaia Health (Germany), BehaVR Inc (US), Ayogo (Canada), Mindable Health GmbH (Germany), Virta Health Corp (US), Hinge Health, Inc. (US), Orexo AB (Sweden) and Freespira (US).The players in the market focus on providing effective products to cater to the unmet needs of customers, increase profitability, and gain a competitive edge in the market.

Noom, Inc. (US) is among the world leaders digital therapeutics market in providing high-quality solutions for weight management, diabetes prevention, and stress reduction. Noom has been awarded multiple grants from the National Institutes of Health and provided the first mobile application recognized by the US CDC as a certified diabetes prevention program. Noom, Inc. launched a program called Noom Mood to expand its behavioral change approach to other conditions, including diabetes, hypertension, and sleep. The company is present in New York (US), Berlin (Germany), Seoul (South Korea), and Tokyo (Japan).
Teladoc Health, Inc. (US) is one of the prominent players digital therapeutics market. The company uses proprietary health signals and personalized interactions to improve health outcomes. It mainly targets diabetes, hypertension, weight management, diabetes prevention, and mental health. Teladoc Health, Inc. launched the Chronic Care Complete program, a chronic condition management solution to help individuals improve their health outcomes while living with multiple chronic conditions. Its programs, such as Chronic Care Complete and myStrength, have been accelerated by the 2020 merger with Livongo, further developing Teladoc Health's ability to deliver true whole-person care with fully integrated clinical and digital solutions responsive to market needs. The merger between Teladoc and Livongo is one of the most significant integrations of competencies and skills in digital health.

Omada Health, Inc (US) is one of the leading player digital therapeutics market. The company provides integrated, virtual care across chronic conditions, a top clinical need for employers and health plans. the company secured USD 73 million from its investors to develop digital care health programs focusing on preventable chronic conditions. The company is focusing on broadening its product offerings beyond diabetes-the company launched the Physician-guided Care Program, a virtual cardiometabolic clinic for hypertension and diabetes patients. The company also partners with many employers, payers, healthcare systems, and pharma companies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724&utm_source=Openpr&utm_campaign=paid&utm_content=referral

Recent Developments:

• Philips and Wellbeing Digital Solutions: Philips announced the acquisition of Wellbeing Digital Solutions (WDS). WDS is a digital therapeutics company that develops digital solutions to improve patient engagement and outcomes in chronic conditions. The acquisition will allow Philips to expand its portfolio of digital health solutions and capabilities in chronic disease management and remote care.

• Novartis and Akili Interactive Labs: Novartis announced that it has entered into a definitive agreement to acquire Akili Interactive Labs, a digital therapeutics company focused on developing treatments for neurological and psychological conditions. Through the acquisition, Novartis will gain access to Akili's digital therapeutics platform, which includes a library of clinical evidence and a portfolio of digital therapeutics programs in development.

• Merck and HealthPrize Technologies: Merck announced that it has entered into a definitive agreement to acquire HealthPrize Technologies, a digital therapeutics company focused on helping patients stay on top of their medications. The acquisition will enable Merck to enhance its digital health offerings and expand its presence in the digital therapeutics market.

• Illumina and GRAIL: Illumina announced that it has entered into a definitive agreement to acquire GRAIL, a digital therapeutics company focused on developing and commercializing multi-cancer early detection products. Through the acquisition, Illumina will gain access to GRAIL's patented technologies and products, which will enable the company to expand its portfolio of healthcare solutions.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724&utm_source=Openpr&utm_campaign=paid&utm_content=referral

The key questions answered in Digital Therapeutics Market report:

1. What are the key trends in the digital therapeutics market?

2. What are the major drivers of the digital therapeutics market?

3. What are the key challenges faced by the digital therapeutics market?

4. What are the key opportunities for the digital therapeutics market?

5. What are the key strategies adopted by market players in the digital therapeutics market?

6. What are the key product offerings of the leading companies in the digital therapeutics market?

7. What is the competitive landscape of the digital therapeutics market?

8. What are the estimated growth rates for the digital therapeutics market in the forecast period ?

Get More Reports:

https://www.prnewswire.com/news-releases/5g-in-healthcare-market-worth-3-667-million-by-2026--exclusive-report-by-marketsandmarkets-301393102.html

https://www.globenewswire.com/news-release/2023/03/06/2620972/0/en/Healthcare-BPO-Market-is-Expected-to-Reach-468-5-billion-MarketsandMarkets.html

https://www.prnewswire.com/news-releases/3d-printing-medical-devices-market-worth-5-1-billion-by-2026--exclusive-report-by-marketsandmarkets-301298589.html

https://www.digitaljournal.com/pr/news/womens-health-diagnostics-market-worth-36-6-billion-by-2025-projected-growth-and-opportunities-finds-marketsandmarkets-

https://www.globenewswire.com/en/news-release/2022/07/19/2482023/0/en/Pharmacy-Automation-Market-worth-8-2-billion-by-2027-Exclusive-Report-by-MarketsandMarkets.html

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.